Welcome to our dedicated page for Innoviva SEC filings (Ticker: INVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innoviva, Inc. filings document a Nasdaq-listed common-stock issuer with a royalty healthcare portfolio, Innoviva Specialty Therapeutics operations, and strategic healthcare investments. Form 8-K reports furnish operating results and financial condition, including royalty revenue, IST net product sales, product-portfolio developments, fair-value changes in investments, and capital allocation activity.
Proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, and equity incentive plan approvals. The record also identifies the company’s common stock, par value $0.01 per share, traded under INVA on the Nasdaq Global Select Market.
Haimovitz Jules reported acquisition or exercise transactions in this Form 4 filing.
Innoviva, Inc. director Jules Haimovitz received equity compensation in the form of restricted stock units and stock options. He was granted 9,786 shares of Common Stock as RSUs and 10,000 non-statutory stock options, each option exercisable at $22.9900 per share.
All of the RSUs and options vest 100% at the earlier of the next annual stockholder meeting or the one-year anniversary of the May 4, 2026 grant, subject to his continuous service as an Outside Director. Vesting accelerates upon death, disability, or a qualifying change in control under Innoviva’s 2026 Equity Incentive Plan. Following the stock award, Haimovitz directly holds 152,692 shares of Common Stock and 10,000 options.
Innoviva, Inc. reported results from its Annual Meeting of Stockholders held on May 4, 2026. Stockholders elected five directors for one-year terms ending at the 2027 annual meeting, including Chief Executive Officer Pavel Raifeld, with each nominee receiving a strong majority of votes cast.
Stockholders approved, on a non-binding advisory basis, Innoviva’s executive compensation and ratified the Audit Committee’s selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved Innoviva’s 2026 Equity Incentive Plan, supporting the company’s ongoing compensation and governance framework.
Innoviva Inc filing shows Vanguard Portfolio Management reports beneficial ownership of 4,288,063 shares of common stock, representing 5.79% of the class. The filing lists 63,112 shares as sole voting power and 4,288,063 as sole dispositive power. The filing is signed by Ashley Grim on 04/29/2026.
Innoviva, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025. The amendment is made to comply with Rule 3-09 of Regulation S-X and updates the exhibits section to add separate financial information for an equity investee.
The filing includes the Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. as of December 31, 2025 and 2024 and for the years then ended, along with the related consent from Armata’s independent registered public accounting firm, Ernst & Young LLP. It also provides new certifications from Innoviva’s principal executive and principal financial officers.
The amendment states that, apart from these added exhibits and certifications, all disclosures remain unchanged from the original Annual Report. As of June 30, 2025, the aggregate market value of Innoviva’s common equity held by non‑affiliates was $1.26 billion, and on February 13, 2026, 74,073,646 shares of common stock were outstanding.
Innoviva Inc: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A stating that, following an internal realignment on January 12, 2026, Vanguard and certain subsidiaries will report beneficial ownership separately. The filing reports 0 shares beneficially owned (0% of the class) of Innoviva common stock. The filing lists Vanguard's address and is signed by Ashley Grim, Head of Global Fund Administration dated 03/27/2026.
Innoviva, Inc. is asking stockholders to vote at its May 4, 2026 annual meeting on corporate governance, pay, auditors and a major new equity plan. Investors will elect five directors, cast an advisory Say-On-Pay vote and consider ratifying Deloitte & Touche LLP as auditor for 2026.
A key item is approval of the 2026 Equity Incentive Plan, reserving 9,000,000 shares of common stock, about 10% of fully diluted shares as of March 9, 2026, to support future stock-based compensation and contingent grants to executives and employees. The proxy highlights strong 2025 results, including net income of $3.30 per diluted share, roughly $645 million in cash and receivables, over $75 million invested in healthcare opportunities and a new $125 million share repurchase program.
Innoviva reported strong growth for 2025, with total revenue rising to $411.3M from $358.7M and net income jumping to $271.2M from $23.4M. Fourth quarter 2025 revenue was $114.6M and net income was $164.2M.
The core royalties portfolio generated $250.3M of 2025 revenue, while Innoviva Specialty Therapeutics delivered U.S. net product sales of $119.2M, up 47% year over year. Cash and cash equivalents increased to $550.9M, supported by $196.9M in operating cash flow. The company highlighted U.S. FDA approval of NUZOLVENCE, the mid‑2025 U.S. launch of ZEVTERA, and initiated a $125M share repurchase program, while indicating an expectation of at least $150M in IST U.S. net product sales in 2026.
Innoviva, Inc. filed its annual report outlining its evolution from a pure royalty business into a diversified biopharmaceutical company. It earns royalties from GSK’s respiratory drugs RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, with tiered rates up to 15% of global net sales.
The company now runs a hospital-focused critical care and infectious disease platform anchored by five FDA-approved products: GIAPREZA®, XACDURO®, XERAVA®, ZEVTERA® and NUZOLVENCE®. These treat severe conditions such as septic shock, carbapenem-resistant Acinetobacter infections, complicated intra-abdominal infections, serious bacterial pneumonias and uncomplicated gonorrhea.
Innoviva highlights regulatory exclusivity, including QIDP designations and extended market protection periods, and notes active competition from numerous branded and generic antibiotics. It also emphasizes disciplined capital deployment, strategic stakes in other healthcare companies and a strategy focused on high unmet medical needs.
Innoviva, Inc. Chief Financial Officer Stephen Basso reported a tax-related share disposition. On February 20, 2026, 1,244 shares of common stock were withheld by the company at $23.39 per share to satisfy income tax obligations on vesting equity awards. After this withholding, Basso directly owns 50,013 shares of Innoviva common stock.
Innoviva, Inc. Chief Executive Officer Pavel Raifeld reported a tax-related share disposition. On the vesting of previously granted equity, 2,986 shares of common stock were withheld by the company at $23.39 per share to cover income tax obligations. After this withholding transaction, Raifeld directly owned 159,290 shares of Innoviva common stock.